MONTREAL, July 31, 2012- The law firm of ROCHON | GENOVA issued a class action on behalf of users of a diabetes drug ACTOS (pioglitazone hydrochloride) residing in Quebec against the manufacturers and distributors of ACTOS, Takeda Pharmaceutical Company, and its affiliates, and Eli Lilly.
ACTOS was approved for sale in Canada in August, 2000 to control blood sugar levels in people with Type 2 (non insulin-dependant) diabetes. A June 2011 study reported to the FDA found a clear link between pioglitazone and increased bladder cancer risk.
The proposed Representative Plaintiff for users of ACTOS is Jimmy Whyte, a 64-year-old retiree living in Kahnawake, Quebec. Mr. Whyte was prescribed ACTOS for the treatment of his Type-II diabetes in November 2008 and was diagnosed with bladder cancer in April 2012.
The allegations raised in the claim have not yet been proven in court. The plaintiff and the prospective class members are represented by the Toronto based law firm of ROCHON | GENOVA .
